ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Submission of Matters to a Vote of Security Holders

ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

Story continues below

On June 22, 2018, OncoMed Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “2018 Annual Meeting”). At the 2018 Annual Meeting, the stockholders of the Company voted on the following proposals, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2018, as supplemented:

Proposal 1:Election of Directors.

The stockholders elected the following individuals to the Company’s Board of Directors:

Nominee

For

Withheld

Broker Non-Vote

Uncast

John A. Lewicki, Ph.D.

29,056,646

48,249

6,154,170

Denise Scots-Knight, Ph.D.

29,044,125

60,770

6,154,170

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.

The stockholders ratified and approved the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

For

Against

Abstain

Broker Non-Vote

Uncast

31,114,942

36,112

4,108,011


About ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

An ad to help with our costs